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224 Abstract
25 Histone demethylases remove transcriptional repressive marks from histones in the nucleus. 
26 KDM6A (also known as UTX) is a lysine demethylase which acts on the trimethylated lysine 
27 at position 27 in histone 3. The KDM6A gene is located on the X chromosome but escapes X 
28 inactivation even though it is not located in the pseudoautosomal region. There is a 
29 homologue of KDM6A on the Y chromosome, known as UTY. UTY was thought to have lost 
30 its demethylase activity and to represent a non-functional remnant of the ancestral KDM6A 
31 gene. However, results with knockout mice suggest that the gene is expressed and the 
32 protein performs some function within the cell.  Female mice with homozygous deletion of 
33 Kdm6a do not survive, but hemizygous males are viable, attributed to the presence of the 
34 Uty gene. KDM6A is mutated in the human condition Kabuki syndrome type 2 (OMIM 
35 300867) and in many cases of cancer.  The amino acid sequence of KDM6A has been 
36 conserved across animal phyla, although it is only found on the X chromosome in eutherian 
37 mammals. In this review, we reanalyse existing data from various sources (protein sequence 
38 comparison, evolutionary genetics, transcription factor binding and gene expression 
39 analysis) to determine the function, expression and evolution of KDM6A and UTY and show 
40 that UTY has a functional role similar to KDM6A in metabolism and development.
41
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45 Abbreviations
46 2-OG, 2-oxoglutarate; CTL, cytotoxic lymphocytes;  EMT, epithelial to mesenchymal 
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54 1. Introduction
55 The first level of coiling of DNA in the nucleus is controlled by the binding of a complex of 
56 histone proteins (the nucleosome) to segments of DNA, which is in turn determined by the 
57 presence or absence of specific post-translational modifications to the histone proteins. The 
58 presence of nucleosomes on a segment of DNA reduces accessibility of that DNA to RNA 
59 polymerase and the DNA is unlikely to be transcribed (reviewed by [1]). Adding or removing 
60 histone modifications can determine whether a gene is expressed. A key modification which 
61 is associated with nucleosome binding is trimethylation of the lysine at position 27 in 
62 histone 3 (H3K27me3). This is a repressive mark, applied by enzymes of the histone 
63 methyltransferase family, which restricts transcription [2, 3]. Release of this repressive mark 
64 requires the activity of histone demethylases, particularly the enzymes lysine demethylase 
65 6A (KDM6A; also known as ubiquitously transcribed X chromosome tetratricopeptide repeat 
66 protein, UTX; OMIM#300128) and lysine demethylase 6B (KDM6B; also known as Jumonji 
67 domain containing protein 3, JMJD3; OMIM#611577) [4-6]. These proteins are characterised 
68 by the presence of a Jumonji C (JmjC) catalytic domain. The gene encoding a third family 
69 member, ubiquitously transcribed Y chromosome tetratricopeptide repeat protein (UTY; 
70 also known as KDM6C; OMIM#400009) [7], was thought to be an inactive degenerate form 
71 of the KDM6A gene with no functional activity but recent studies suggest it retains some 
72 residual catalytic function [8, 9] and may also be involved in methylation-independent 
73 activities [10], as outlined in Section 2. 
74 The KDM6A gene is located on the X chromosome in eutherian mammals [11]. Although not 
75 located in the pseudoautosomal region, KDM6A escapes X-inactivation [12, 13] and its level 
76 of expression reflects the number of X chromosomes [14]. Eutherian females have higher 
77 levels of this protein and its mRNA than eutherian males [13, 15]. However, eutherian males 
78 also carry UTY [16], the homologue of KDM6A on the Y chromosome, and its expression 
79 level correlates with the number of Y chromosomes [14]. X chromosome genes with a Y 
80 chromosome paralogue generally have a role in transcription, translation and nucleic acid 
81 binding [17] and hence are central to regulation of gene expression during development, 
82 immune function, cell proliferation and differentiation and tumorigenesis. Here we review 
483 the function, expression and evolution of the KDM6A and UTY genes and highlight the 
84 functional similarity of the two proteins.
85
86 2. Functions of KDM6A and UTY
87 KDM6A functions both through its demethylase activity [5, 18] and through a structural role 
88 which may be mediated by the protein binding capacity of the tetratricopeptide repeats 
89 (TPRs) [4, 19] [20] (Section 3). These functions can be distinguished through use of 
90 catalytically inactive versions of the protein or through the use of demethylase inhibitors. 
91 Human UTY has reduced catalytic activity [9] but retains the protein binding capacity of 
92 KDM6A. 
93 2.1 H3K27 in gene regulation
94 Gene expression can be repressed by methyl groups added to the lysine 27 of histone 3 
95 (H3K27) by methyltransferase EZH2 [21], part of polycomb repressive complex 2 (PRC2) [22]. 
96 Trimethylation of H3K27 (H3K27me3) is involved in control of developmental genes and also 
97 marks the inactive X chromosome [23]. Removal of the methyl groups by histone lysine 
98 demethylases allows acetylation of H3K27 (H3K27ac) by histone acetylases such as CREBBP 
99 [24] (see Supplementary Figure 1), converting the histone to the active state and opening 
100 the chromatin for transcription factor binding and RNA polymerase recruitment. H3K27me3 
101 and H3K27ac are thus antagonistic to each other. In contrast, trimethylation of the lysine at 
102 position 4 in histone 3 (H3K4me3) is an activating modification [25, 26] while 
103 monomethylation of the same lysine is associated with enhancer activity. Methylation of 
104 H3K4 is mediated by a COMPASS-like complex [20] in which the methyltransferases KMT2C 
105 (also known as MLL3; OMIM#606833) or KMT2D (also known as MLL2, MLL4 and ALR; 
106 OMIM#602113) act on H3K4, facilitated by H3K27 demethylation (by KDM6A) and 
107 subsequent acetylation. Promoters that contain both H3K27me3 (repressing) and H3K4me3 
108 (activating) are poised for transcription. Demethylation and acetylation of H3K27 then 
109 allows transcription to proceed [27, 28]. There may therefore be a dynamic relationship 
110 between the demethylase and the methyltransferase in the MLL complex. A model has been 
111 proposed where there is coordinated removal of repressive marks, addition of active marks, 
112 and displacement PRC1 (which ubiquitinates H2A, another repressive mark) and PRC2 to 
5113 give tight regulation of gene expression during differentiation [29]. This potential to radically 
114 alter the epigenetic landscape can create new gene expression patterns as cells undergo 
115 changes in state through for example differentiation or activation [30].
116 2.2 Activity of KDM6A
117 KDM6A is a member of the family of 2-oxoglutarate (2-OG) and Fe(II)-dependent JmjC 
118 dioxygenases which function to demethylate histones or nucleic acids (Section 2.1) [31-34]. 
119 The histone lysine demethylase (KDM) enzymes use 2-OG and molecular oxygen to 
120 hydroxylate the methyl group(s) of a methylated lysine within the histone protein, forming 
121 an unstable carbinolamine intermediate which decays to release formaldehyde, leaving the 
122 lysine with one less methyl group [33, 34] (Supplementary Figure 1).  KDM6A targets H3K27 
123 and recombinant human KDM6A was able to successively remove each of the three 
124 repressive methyl groups from protein mixtures containing histone 3 [35]. It is highly 
125 specific for H3K27me3 and does not demethylate other lysines in histone H3 or H4 [32]. 
126 KDM6A is also a component of the KMT2C/KMT2D COMPASS-like complex [27, 28]. Recent 
127 studies of human HEK293T cells suggest that the participation of KDM6A in the complex 
128 relies on demethylase-independent functions [36].
129 Network analysis has shown that KDM6A interacts with a range of proteins. In one study 
130 based on a protein-protein interaction network, interaction partners for KDM6A were found 
131 to fall into three categories [37]. The majority of the primary interacting proteins were 
132 involved in chromatin modification through histone methylation. These included KMT2D, 
133 consistent with the role of KDM6A in the MLL2 complex. The similarity of the roles of 
134 KMT2D and KDM6A is highlighted by the very similar phenotypes produced by KMT2D and 
135 KDM6A gene mutations, as discussed further in Section 5.2. A second cluster of primary and 
136 secondary associated proteins contained transcription factors. The third cluster was of 
137 proteins involved in cell cycle regulation, with the key interacting partner being the 
138 retinoblastoma like protein RBL2 (also known as p130).
139 Although the histone demethylase activity of KDM6A takes place in the nucleus, several 
140 reports have shown that native KDM6A protein is largely located in the cytoplasm of 
141 immortalised human mammary epithelial cells and mouse  fibroblasts [38-40]. A single 
142 nuclear localisation signal was identified in KDM6A and UTY (RRRK at amino acids 1089-
6143 1092) [38], considered insufficient for efficient transport through the nuclear membrane 
144 [38-40]. This suggests that KDM6A may also demethylate or hydroxylate cytoplasmic 
145 proteins, or that the noncatalytic protein binding capacity may be important in assembling 
146 protein complexes in the cytoplasm. 
147 2.3 KDM6A in development 
148 KDM6A is an important determinant of cell fate and cellular identity during development 
149 through its control of pluripotency and lineage specific genes.  A major target is the HOX 
150 gene family. Reduction of KDM6A level by RNA interference resulted in increased 
151 methylation at HOXD10, HOXD11 and HOXD12 genes in HeLa cells [35]. KDM6A was 
152 selectively localised to HOX loci in human primary fibroblasts but in embryonic stem cells, 
153 where HOX genes are largely transcriptionally silent, it was excluded from HOX loci [35]. 
154 KDM6A binds to the human and mouse HOXB1 promoter and is required for expression of 
155 the HOXB1 gene [29]. Retinoic acid treatment of human NT2/D1 embryonal carcinoma cells 
156 and mouse embryonic stem cells increased the binding of KDM6A to the HOXB1 promoter, 
157 decreased the level of H3K27me3 and increased H3K4me3 [29], all consistent with gene 
158 activation. Inhibition of the zebrafish utx1 (KDM6A orthologue) disrupted posterior 
159 development [35] and mutation or inhibition of a Caenorhabditis elegans orthologue 
160 resulted in abnormal gonadal development [29]. During division of stem cells, H3K27me3 is 
161 largely absent from cells in S phase and the re-establishment of trimethylation is delayed by 
162 histone demethylase activity in embryonic stem cells [41] which may be important in 
163 promoting differentiation. 
164 Kdm6a-null mouse embryonic stem cells were unable to differentiate into mesoderm [42, 
165 43] and a number of studies have shown involvement of KDM6A protein in mesenchymal 
166 cell differentiation. Knockout of Kdm6a in mouse C2C12 cells affected differentiation to 
167 osteoblast phenotype [44] and removal of Kdm6a in male mouse embryonic stem cells 
168 reduced their potential to differentiate towards the adipocyte lineage [45]. In murine bone 
169 marrow derived mesenchymal stem cells, Kdm6a mRNA reduced during adipogenic 
170 differentiation, mediated by microRNA miR-199a-3p [46]. Transfection with Kdm6a cDNA 
171 could alleviate the loss of osteogenic and adipogenic differentiation caused by 
172 glucocorticoid treatment of immortalized murine osteogenic progenitor cells [45, 47]. 
7173 Knockdown of KDM6A in human primary periodontal ligament stem cells reduced their 
174 ability to differentiate to chondrocytes, through inhibition of expression of SOX9 [48]. 
175 Recently differential methylation and expression of KDM6A during human muscle 
176 development in vitro has been demonstrated [15]. Clearly, KDM6A is an important molecule 
177 in the early and late stages of differentiation of mesenchymal cell types. KDM6A has also 
178 been identified as a critical regulator for migration of mouse hematopoietic stem cells and 
179 zebrafish primordial germ cells [49].
180 KDM6A controls DNA methylation during oogenesis and early embryonic development in 
181 mouse, pigs and cattle [50-52]. Overexpression of Kdm6a improved the development of 
182 mouse embryos derived by single cell nuclear transfer, possibly through suppression of Xist-
183 mediated X inactivation of both X chromosomes [51]. KDM6A also promotes reprogramming 
184 of mouse somatic cells to pluripotency [53], which may indicate that it is involved in the 
185 reprogramming of the developing embryo. A role in early development and fertility is 
186 supported by the observation that variation in KDM6A was associated with litter size in 
187 goats [54, 55]. Taken together these results suggest that KDM6A has an important role in 
188 regulating chromatin during development so that transcription factors can access genes 
189 required for specific differentiation pathways.
190 Consistent with its role in differentiation and development, KDM6A also acts as a tumour 
191 suppressor gene. Loss of KDM6A promotes tumor growth and is associated with aggressive 
192 cancer progression in multiple human tumor types including pancreatic cancer and B cell 
193 lymphoma [56-59]. KDM6A repressed the ETS (pro-oncogenic) program and maintained the 
194 GATA (tumor suppressive) program during mouse myeloid leukemogenesis [10] and 
195 inhibited cell invasion and cell growth through retinoblastoma (Rb) activated genes in 
196 human A549 and LC2-ad lung cancer cell lines [60].  Overexpression of KDM6A in these lung 
197 cancer cells inhibited TGFβ-induced epithelial-to-mesenchymal transition (EMT) although 
198 knock down of KDM6A to about 40% of wild type did not induce EMT [60]. However 
199 demethylation by KDM6A appears necessary for tumor maintenance through activation of 
200 the NOTCH pathway [61]. The impact of KDM6A varied between urothelial carcinoma cell 
201 lines, dependent in part on the status of KMT2C and KMT2D [62]. The paradoxical roles of 
202 KDM6A in both suppressing and supporting oncogenesis have been reviewed recently [20, 
203 63].
8204 2.4 Other roles of KDM6A
205 Other functions of KDM6A have also been suggested. It may take part in the response of 
206 macrophages to bacterial and viral challenge through both methylase dependent and 
207 independent mechanisms [64]. The demethylase activity is also required for expansion of 
208 natural killer T cells in mice [65]. An association with blood glucose regulation is suggested 
209 by the hyperinsulinemia observed in some patients with haploinsufficiency of KDM6A [66, 
210 67]. This association is supported by the observation that KDM6A activity is inhibited by the 
211 antidiabetic biguanide metformin (which binds to the demethylase catalytic region) [68]. In 
212 addition, KDM6A expression was correlated with circulating HDL-cholesterol levels and 
213 silencing of KDM6A in a cell lysate reduced HDL-cholesterol, APOA1 and LIPC levels [53, 69, 
214 70]. Females, with two copies of KDM6A, are more sensitive to insulin than males and the 
215 expression of KDM6A in the liver of obese human females was higher than in obese males 
216 [69]. One study suggests that KDM6A controls adipogenesis through regulation of c-Myc at 
217 specific differentiation stages (Section 2.3) [45]. Thus, KDM6A has diverse functions during 
218 normal and abnormal development across vertebrate species.
219 2.5 Functions of UTY
220 Like KDM6A, UTY is a 2-OG- and Fe(II)-dependent oxygenase [31, 32]. The human UTY 
221 protein has lower enzymatic activity than KDM6A, but recent studies suggest it may have 
222 some residual function [9] although it is not clear whether this is sufficient to contribute 
223 physiologically to H3K27 demethylation. Homozygous deletion of Kdm6a (Kdm6a -/-) in 
224 female mice resulted in fully penetrant embryonic lethality [8].  Kdm6a-/- embryos at E10.5 
225 stage displayed severe deformities of neural tube, yolk sac and heart, and their entire 
226 development was delayed [11]. These embryos were dead and reabsorbed by stage E12.5. 
227 However, male embryos (Kdm6a-/Uty+) developed to term and there was a subset (~25%) 
228 who survived to adulthood. These male mice were smaller than wildtype, with reduced 
229 lifespan, but they were fertile and viable. This disparity between male and female knockout 
230 animals was thought to be due to compensation for the absence of Kdm6a by Uty [11]. 
231 Further experiments generated Kdm6a-/Uty- male mice, which shared the fate of 
232 homozygous Kdm6a-/- female mice and died in utero with heart deformities. 
9233 The mechanism by which UTY compensates for loss of KDM6A is likely to be largely 
234 independent of the demethylase activity, since the activity of UTY is low [8, 9]. In addition, 
235 UTY can produce a similar phenotype to catalytically inactive KDM6A [10]. Like KDM6A, UTY 
236 binds to the Brachyury gene promoter, suggesting one route by which it can influence 
237 differentiation. Embryonic stem cells from male Kdm6a-/Uty+ mice showed some potential 
238 to differentiate into mesoderm, unlike cells from female Kdm6a-/- mice [45]. While this was 
239 attributed to residual KDM6A activity in the male mice [45], it seems likely that UTY also 
240 contributed to the effect since no KDM6A protein was detected in the Kdm6a-/Uty+ 
241 embryonic stem cells.
242 A number of studies of human and mouse cancer models have also shown that UTY can 
243 compensate in some way for the absence of KDM6A. During myeloid leukemogenesis, 
244 KDM6A repressed the ETS oncogenic transcriptional program and activated the GATA 
245 tumour suppressive program [10]. Removal of KDM6A reversed this effect but it could be 
246 rescued by either catalytically inactive KDM6A or by UTY [10]. Similarly in a mouse 
247 lymphoma model, male mice lacking a functional Kdm6a gene but retaining Uty survived 
248 longer than females with both Kdm6a genes knocked out. However these males had poorer 
249 survival than heterozygous females, indicating that UTY is not as effective as KDM6A as a 
250 tumour suppressor [58]. The reduced catalytic activity of UTY was not sufficient to promote 
251 natural killer T cell development in mice [65]. Experiments where phenotypic and 
252 chromosomal sex were uncoupled in mice showed that the Y chromosome contributed to 
253 protection from bladder cancer, consistent with the observation that loss of the Y 
254 chromosome in bladder cancer is associated with a worse prognosis [71]. UTY is also 
255 implicated in prostate cancer and is part of a network that controls prostate differentiation 
256 initiated by NKX3.1 signaling to EHMT2 (also known as G9a) which then binds to the 
257 promoter of UTY initiating transcription of prostate specific genes and suppression of non-
258 prostate genes [72].
259 These results indicate that UTY performs some function [11] and has tumour suppressor 
260 activity [10]. Human UTY has a low level of H3K27me3 demethylase activity in vitro [9]. UTY 
261 might be partially functionally redundant with KDM6A at least in some cells and tissues. 
262 However, it is not certain whether this depends on its demethylase activity or its protein-
263 protein interactions.
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265 3. Evolutionary analysis of H3K27me3 demethylases KDM6A and UTY 
266 The three H3K27 demethylases contain a JmjC domain near the C terminus (Figure 1A).  The 
267 JmjC domain is found in a large family of proteins present across vertebrates and 
268 invertebrates. The KDM proteins form a subgroup of the enzyme family of 2-OG- and Fe(II)-
269 dependent oxygenases which regulate transcription and/or chromatin structure, many 
270 through histone demethylation (Section 2) [18]. KDM6A and UTY also carry a number of 
271 tetratricopeptide repeats (TPRs) (Figure 1A) which are important for protein-protein 
272 interactions and the assembly of multiprotein complexes [4, 19]. The pervasiveness of the 
273 JmjC domain across animal phyla indicates that this evolutionarily conserved sequence has 
274 an important role in animal biology.
275 3.1 Comparison of KDM6A and UTY genes, transcripts and proteins
276 A number of different transcripts have been reported for the KDM6A and UTY genes, arising 
277 from alternative splicing. The KDM6A gene gives rise to 14 different splice variants with 10 
278 predicted protein-coding transcripts (Table 1; Figure 1B). These range from 671 bp to 5924 
279 bp (Ensembl Browser). Some of the shorter splice variants do not code for the KDM6A JmjC 
280 or TPR functional domains (for example transcripts 205, 203, 206 and 214; Table 1). Mouse 
281 Kdm6a shows 10 transcripts (six potentially protein coding). Similarly to KDM6A, UTY has 16 
282 possible transcripts the in the Ensembl database, and 13 of them are potentially protein-
283 coding (Table 1, Figure 1B), with various transcript and peptide lengths. Some splice variants 
284 do not contain the JmjC domain or full-length TPR domains. One study [73] detected 284 
285 alternative transcripts for UTY, but these findings have not been validated by other reports. 
286 Mouse Uty produced 12 transcripts (eight protein coding).
287 To assess the promoter architecture of human KDM6A, we obtained data from the 
288 FANTOM5 Browser [74] which includes results from over 1,800 tissues and cells. This 
289 identified a single transcription start site (p1@KDM6A), and no other alternative promoters 
290 were detected or have been described (Figure 1A). In mouse, four transcription start sites 
291 were identified; three are within 100 bp of each other and would not alter the translated 
292 region and the fourth is 400 bp away at the beginning of the first coding exon. The FANTOM 
293 5 database does not show any alternative human UTY transcription start sites to the main 
11
294 promoter named p1@UTY (Figure 1B). Mouse Uty shows three transcription start sites 
295 within 150 bp and likely representing a single promoter. Therefore it seems diversity is 
296 generated for both human and mouse UTY and KDM6A through alternative splicing rather 
297 than differential promoter usage.
298 The annotated human KDM6A and UTY transcripts shows up to 88% cDNA homology and 
299 86% predicted amino acid homology (Figure 2). The third member of the family, KDM6B, 
300 shows only 29% cDNA homology with both KDM6A and UTY cDNA, and even less for the 
301 protein, although all three proteins contain a JmjC domain, which is conserved across all 
302 members of the KDM family [75]. The sequences of the KDM6A and UTY TPR domains are 
303 very similar. The catalytic residues in the JmjC domains are also conserved with only five 
304 amino acid differences.  The reduction in UTY demethylase activity compared to KDM6A is 
305 thought to be due to a glutamate to serine substitution in the JmjC domain (green rectangle 
306 in Figure 2) [9]. The linker sequence between the TPR and JmjC domains is not as highly 
307 conserved as the functional domains (not shown). Since a number of the putative protein-
308 coding transcripts for both UTY and KDM6A would not include the UTY or KDM6A functional 
309 domains, it is not clear whether these incomplete peptides are able to carry out the 
310 functional roles of these two enzymes or whether they may have a regulatory role. 
311 3.2. Evolutionary analysis of KDM6A 
312 According to the Ensembl database, the JmjC domain is present throughout living species 
313 (see also [18]). Saccharomyces cerevisiae (yeast) has two genes with the TPR domains (CYC8 
314 and YNL313C). In Caenorhabditis elegans (nematode) four genes (jmjd3.1, jmjd3.2, jmjd3.3, 
315 utx-1) have both a section of TPR repeats and a JmjC domain. Drosophila melanogaster 
316 (fruitfly) has a single Utx gene with four TPR repeats and a JmjC domain. The presence of 
317 these sequences in species so phylogenetically distant from the mammals indicates that 
318 they represent ancient functions that have been maintained through evolution.
319 The human KDM6A gene has 111 orthologs in different species. As might be expected, 
320 placental mammal homologues are most similar to the human gene; as the evolutionary 
321 distance of other species from humans increases, the available annotations become less 
322 clear and the homology decreases. The Gene Tree generated by Ensembl is shown in 
12
323 Supplementary Figure 2. As with the human and mouse, the annotated KDM6A genes from 
324 other species including non-mammalian species show multiple splice variants.
325 KDM6A is located on human X chromosome in band Xp11.3 and at a syntenic region of the X 
326 chromosome in other eutherian mammals, whereas it is located on an autosome 
327 (chromosome 4) in opossum (a marsupial) and is predicted to be located on chromosome 18 
328 in platypus (a monotreme with five different X chromosomes, none homologous to the 
329 human X) [76]. In birds and fish, where the female is heterogametic (ZW) and the male is 
330 homogametic (ZZ), KDM6A is also located on autosomes. In these species there is a block of 
331 synteny with the human X chromosome extending to one side of KDM6A, but genes on the 
332 other side map to human chromosome 21. This would suggest that the KDM6A gene 
333 became associated with the sex chromosome with a block of other genes, somewhere at 
334 the time when the common ancestor for all eutherian mammals evolved. Therefore, only 
335 eutherian males are hemizygous for KDM6A, and might be expected to have a functional  
336 UTY to compensate for the reduced dosage, as KDM6A escapes X inactivation in human 
337 females [12]. 
338 3.3 UTY and the Y chromosome
339 Despite recent advances in high throughput sequencing of genomes of various organisms, 
340 the Y chromosome sequence has been frequently overlooked. Most genome releases in 
341 Ensembl did not include the Y chromosome, probably due to the small size, presumed low 
342 gene content and a large number of repetitive sequences which hinder scaffold assemblies 
343 [77]. In the current Ensembl release, only 18 species have an annotated SRY gene, the key 
344 functional gene on the Y chromosome which is responsible for the initiation of male 
345 phenotype. This indicates that Y chromosome sequences are underrepresented in the 
346 current genome assemblies. Human UTY is listed as having 54 orthologs but the majority of 
347 these map to the X chromosome in eutherian mammals and to autosomes in other species, 
348 and represent instances of KDM6A (see Supplementary Figure 2). Ensembl contains 
349 annotated UTY genes for human and other primates, mouse, goat, pig, amur tiger and cow, 
350 which all seem to be in syntenic regions of the Y chromosome. There are also probable UTY 
351 genes for donkey, polar bear, Damara mole rat and red fox, as shown in Supplementary 
352 Figure 2 and a UTY gene has been reported for the yak (a genome that is not in Ensembl) 
13
353 [78]. From the limited reports of Y chromosome sequencing it appears that UTY is one of the 
354 few Y chromosome genes that is present as a functional gene in all eutherian species 
355 studied so far [77]. In addition, multiple alternatively spliced transcripts have been seen for 
356 all UTY genes.
357 The original placental and marsupial (therian) Y chromosome, containing the sex-
358 determining gene SRY, emerged approximately 180 million years ago [79]. UTY is located 
359 together with other Y-chromosome genes such as ZFY, USP9Y, DDX3Y and TMSB4Y [79] in a 
360 Y chromosome region that stopped recombining with the X approximately 100 million years 
361 ago [80]. Human UTY lies right next to two other genes with X chromosome equivalents, 
362 USP9Y and DDX3Y, and a non-coding element TTTY15. KDM6A also neighbours the 
363 equivalent genes on the X chromosome, USP9X and DDX3X, although not as closely. 
364 UTY has remained in a male-specific Y chromosome region (MSY), with USP9Y and DDX3Y, 
365 throughout eutherian Y chromosome evolution despite rampant rearrangements of the Y 
366 chromosome [77]. The high microsyntenic conservation of this cluster of genes 
367 USP9Y+DDX3Y+UTY suggests that they might be co-regulated, possibly by the ‘testis-specific’ 
368 non-coding element TTTY15 [77] which was identified as an enhancer in the FANTOM5 
369 study [78]. In the extensive FANTOM5 database strong expression of these genes was found 
370 in cells of the hematopoietic lineage, primarily in T and B lymphocytes. Expression of USP9Y 
371 was low, with a maximum of 30 tags per million (TPM [81]) in the ARPE retinal epithelium 
372 line, while UTY and DDX3Y had their highest expression in eosinophils and T cells 
373 respectively (Table 2). TTTY15 was highly expressed in ARPE cells and lymphocytes, allowing 
374 the possibility that it regulates the other two genes in these tissues. Network analysis based 
375 on the FANTOM5 data for more than 1,000 human tissues, cancers and cell lines showed 
376 that KDM6A, UTY, DDX3Y and USP9X have similar expression patterns while USP9Y and 
377 TTTY15 are similar to each other in their expression patterns.
378 Positive directional selection on some codons within primate UTY and USP9Y genes has 
379 been detected [82], suggesting that advantageous changes may have occurred during the 
380 evolution of these genes [83].  Their X chromosome homologues are under a strong 
381 purifying (negative) selection [82], indicating that variants which would have deleterious 
382 impact on fitness are being purged by selection. This means that any KDM6A missense 
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383 mutation is likely to negatively affect the cell, but UTY diversity may have been encouraged 
384 during evolution and may compensate for the accumulation of deleterious mutations in the 
385 non-recombining Y chromosome [82]. The changes in UTY might be beneficial with a male-
386 specific function. It is not clear whether the reduction/loss of the demethylase/hydroxylase 
387 function of UTY was driven by positive selection or was a consequence of evolutionary 
388 processes acting on the degenerating Y chromosome. Nevertheless, it seems that UTY with 
389 lower or no demethylase activity is sufficient to rescue the embryonically lethal Kdm6a-/- 
390 genotype and substitute for KDM6A at least to some extent. 
391
392 4. Co-regulation of UTY and KDM6A
393 To explore further the functional impact of the similarity of the UTY and KDM6A proteins, 
394 the FANTOM5 human dataset was analysed to determine whether or not the genes were 
395 expressed at the same time in the same tissues (which would suggest that they are 
396 controlled by the same regulators) or with opposite expression patterns (suggesting that 
397 there is a mechanism to regulate the combined level of the mRNA/proteins within a cell). An 
398 initial survey showed that many samples did not express UTY. However, all testes and 
399 prostate samples did express UTY, suggesting that those where UTY was not detected were 
400 from female donors. This was validated where possible using the sample metadata 
401 (http://fantom.gsc.riken.jp/5/sstar/Main_Page). KDM6A and UTY expression levels (TPM)  
402 were strongly positively correlated across the data set of male samples (Pearson’s 
403 correlation r = 0.720, N = 517; Figure 3A). These results show that UTY probably does not 
404 compensate for low KDM6A expression, since when there was high UTY expression, there 
405 was also high KDM6A expression, consistent with co-regulation of the two genes across all 
406 cell types, as previously reported for mouse brain [13]. 
407 A strong correlation was found in the subset of samples from tissues and primary cell lines (r 
408 = 0.728, N = 439; Figure 3B). The association was much weaker when only cancerous 
409 samples were included (r = 0.322, N = 78; Figure 3C), consistent with the high level of 
410 mutation of KDM6A (and to some extent UTY) in cancer [20] and suggesting that some of 
411 these mutations affect the regulatory motifs controlling the binding of transcription factors. 
412 KDM6B expression did not have a high correlation with UTY or KDM6A expression (r = 0.469, 
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413 N = 1829 with KDM6A and r = 0.261, N = 517 with UTY), indicating that it is regulated 
414 independently and has a distinct expression pattern compared with KDM6A and UTY. 
415 To understand the potential co-regulation of UTY and KDM6A, an analysis of transcription 
416 factor (TF) motifs was performed, using Harmonizome 
417 (https://amp.pharm.mssm.edu/Harmonizome/ ) [84], a relational database of functional 
418 associations between genes and proteins, and their attributes. Different predicted TF 
419 binding sites for KDM6A, UTY and KDM6B were identified. Several databases for TF binding 
420 sites were used (TRANSFAC, JASPAR, CHEA and ENCODE [85-90]). TRANSFAC and JASPAR 
421 predict TF binding using known binding site motifs, whereas CHEA and ENCODE use ChIP-
422 seq data. The TRANSFAC dataset also provided curated data, which were manually selected 
423 from low-throughput or high-throughput TF functional studies. A number of TF binding sites 
424 appeared common to KDM6A and UTY, especially in the TRANSFAC curated dataset, where 
425 all 10 UTY TF were shared by KDM6A. Fewer TF sites were shared between KDM6A and 
426 KDM6B or UTY and KDM6B.  In the ChIP-seq based data the UTY promoter did not have as 
427 many TF binding sites as the other two. In both CHEA and ENCODE datasets KDM6A and 
428 KDM6B had a number of TF binding sites in common, unlike UTY. The ENCODE dataset also 
429 showed 32 different TF sites which were common to all three gene promoters. A summary 
430 of these results is presented in Supplementary Figure 3.
431 The pathway commons protein-protein interactions database in Harmonizome showed that 
432 UTY and KDM6A interact with each other physically. KDM6A and UTY also shared a  number 
433 of common protein interaction partners including components of the H3K4 methylation 
434 complex such as KMT2B, KMT2C and RBBP5 (Supplementary Figure 4) suggesting that UTY 
435 may perform demethylation functions. The NURSA Protein Complexes dataset of 
436 Harmonizome showed that UTY binds to the same protein complexes as KDM6A. It is not 
437 clear whether UTY binds to this complex independently or only in the presence of KDM6A. It 
438 may have a catalytically or structurally autonomous function and could therefore target 
439 different substrates. Further investigation into protein-protein interactions with KDM6A 
440 should prove interesting.
441 Although UTY may serve a separate male specific function, for example in testes, it appears 
442 to be expressed in a wide range of cell types (as shown in the BioGPS dataset and FANTOM5 
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443 data). The findings presented in this section suggest that in general KDM6A and UTY have 
444 shared regulation, which may allow for survival of males by compensating for the 
445 haploinsufficiency of KDM6A. In contrast, KDM6B appears to have very different regulation 
446 and showed little redundancy with KDM6A and UTY, indicating that this protein likely has an 
447 independent role.
448
449 5. Clinical significance of KDM6A and UTY
450 X chromosome genes with a Y chromosome homologue (many of them coding for 
451 chromatin-modifying enzymes including KDM6A) are needed for proper gene regulation and 
452 are potentially sensitive to altered dosage [17]. In particular, X chromosome genes that 
453 escape X inactivation may be subject to a dose response which leaves males 
454 haploinsufficient, unless the Y homologue has similar activity. Abnormal modification of 
455 histone proteins has been associated with multiple diseases in humans and animal models 
456 [91]. This means that a range of clinical conditions are likely to be associated with 
457 abnormalities of KDM6A. The analysis of KDM6A and UTY gene expression (Section 4) 
458 suggests that the two genes are co-regulated and that UTY might compensate in males for 
459 the single copy of KDM6A. 
460 5.1. KDM6A and UTY in cancer
461 KDM6A has been identified as a tumour suppressor gene (Section 2.3). Consistent with this, 
462 KDM6A mutation is common in a range of hematological and non-hematological 
463 malignancies [10, 92, 93], although the target genes and impact vary according to tissue 
464 (reviewed by [94]). It is frequently mutated in pediatric cancers [95]. In leukemias, 
465 mutations have been detected both within and outside the catalytic domain (reviewed in 
466 [96]).  In mice Kdm6a loss constitutes a preleukemic state [10]. In contrast, KDM6A 
467 mutation was only found at relapse in human acute myeloid leukemia [97] and its loss 
468 enhanced resistance to cytarabine treatment. UTY mutation was found at relapse in one 
469 case [97]. Low KDM6A expression at diagnosis also correlated with poorer clinical outcome 
470 [97]. In non-invasive bladder cancer KDM6A mutation was common and could affect the 
471 catalytic or non-catalytic domains of the protein [98]. KDM6A loss or somatic mutation was 
472 also found in bladder cancer where it led to enhanced tumor growth in vivo and 
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473 proliferation in vitro [99-101]. KDM6A loss may be associated with aggressive tumor 
474 progression in a number of malignancies [94], but in contrast overexpression was associated 
475 with proliferation and invasion in breast cancer [102] leading to a worse prognosis [103] and 
476 knock down of KDM6A activated apoptosis in cancer cells [61] suggesting a complex 
477 contribution of KDM6A to both tumor suppression and maintenance or progression [20].
478 Many cancers are more prevalent in males than females and loss of the Y chromosome 
479 within the tumour is associated with increased risk of all-cause mortality, including from 
480 non-hematological malignancy [104]. In a mouse model of bladder cancer, XY female mice 
481 and XX male mice had similar survival rates, lower than XX females but higher than XY males 
482 [71] suggesting independent effects of sex hormones and chromosomes on cancer risk. Both 
483 UTY and KDM6A knockout enhanced proliferation of two male urothelial bladder cancer cell 
484 lines [105] and loss of UTY was also observed in 12% of urothelial bladder carcinomas [100]. 
485 UTY knockout increased cell proliferation to the same rate as KDM6A knockout, and double 
486 knockout of KDM6A and UTY increased it even more. The authors argue this is due to the 
487 loss of dosage-dependent suppression effect of KDM6A/UTY in urothelial cancer. The 
488 positive correlation between expression of KDM6A and UTY (Section 4) was disrupted in 
489 cancer cells which may result in disrupted homeostasis of demethylase activity. Thus, both 
490 KDM6A and UTY play a complex role in the initiation and progression of tumors.
491 5.2 KDM6A in genetic conditions
492 KDM6A missense, nonsense and deletion mutations were found to cause some cases of 
493 Kabuki syndrome (OMIM #300867) [106-108], which is a rare dominant multi-systemic 
494 disorder first reported in Japan by two research groups [109, 110]. Patients with Kabuki 
495 syndrome have an unusual facial appearance (resembling the traditional make up by 
496 Japanese Kabuki artists) intellectual disability, scoliosis, radiographic abnormalities of the 
497 skeleton, cardiovascular abnormalities, increased susceptibility to infections and other 
498 manifestations [111]. The majority of cases were found by whole-genome sequencing to 
499 have mutations in KMT2D (see OMIM #147920). As discussed in Section 2, KMT2D is part of 
500 a complex which also includes KDM6A, involved in coordinating the removal of repressive 
501 marks and deposition of activation marks on histone 3 [25, 29], promoting gene expression. 
502 Cases with KDM6A mutation were more likely to have short stature and growth retardation 
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503 [106]. This is consistent with the role of KDM6A in growth and development (Section 2.3). 
504 Females were less severely affected than males [112], suggesting that the normal KDM6A 
505 gene on the other X chromosome of the females contributes more than UTY on the Y 
506 chromosome of the males. KDM6A dysfunction was also associated with hyperinsulinemia 
507 [67] (Section 2.5). To date, 33 germline mutations in KDM6A gene have been found in a 
508 comprehensive study of Kabuki syndrome mutations [112]. No mutations have been 
509 reported in UTY although two cases had structural rearrangements of the Y chromosome 
510 [113] with breakpoints away from the UTY gene. 
511 Patients with Turner syndrome (45X karyotype) have some Kabuki syndrome features 
512 including short stature (reviewed in [114]). Turner syndrome is the only human 
513 chromosomal monosomy where affected individuals may survive after birth. Nevertheless, 
514 it significantly affects fetal mortality as only 1% of 45X monosomy foetuses survive to term 
515 [115] presumably reflecting haploinsufficiency of genes in the pseudoautosomal (non-X-
516 inactivated) region and other genes that escape X-inactivation such as KDM6A. Turner 
517 syndrome patients surviving to adulthood are most probably mosaic cases [115] where 
518 some cells have two X chromosomes or an X and a Y chromosome. Network analysis found 
519 that KDM6A is a key regulator in Turner syndrome [116]. KDM6A is a potential candidate 
520 gene for premature ovarian failure in Turner syndrome [117, 118] because of its role in 
521 fertility and pluripotency (Section 2.3), and may be involved in gonadal dysgenesis [119]. 
522 However, females with Kabuki syndrome due to KDM6A inactivating mutation do not 
523 generally suffer this problem. KDM6A has also been associated with hyperinsulinemia in 
524 infants with Turner syndrome [66]. KDM6A was found to have reduced expression in 
525 peripheral blood RNA from 45X karyotype individuals compared with 46XX karyotype 
526 individuals [117], which is consistent with the observation that KDM6A escapes X-
527 inactivation [12].
528 The similar phenotypes observed in Kabuki syndrome with KDM6A mutation and Turner 
529 syndrome with X chromosome aneuploidy may result from a threshold effect where a 
530 certain level of KDM6A/UTY gene expression is needed for proper developmental function, 
531 either two functional copies of KDM6A or one copy of KDM6A and one of UTY [106]. This 
532 threshold level must be higher than that generated by a single copy of KDM6A. Kabuki 
533 syndrome female patients can have skewed inactivation of the X chromosome for the 
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534 KDM6A mutation [67, 106], which could raise the overall level of KDM6A higher than in 
535 males with KDM6A mutation (who may have a more severe manifestation [112]), but still 
536 less than the expression level reached with two functional KDM6A copies. Thus, this 
537 hypothesis needs to be investigated further by assessing absolute levels of KDM6A and UTY 
538 mRNA and protein expression in the same male and female tissues.
539 Given that KDM6A is a tumor suppressor gene, it might be expected that individuals with 
540 Kabuki syndrome caused by KDM6A mutation would be predisposed to a range of cancers. A 
541 number of sporadic cancers have been reported in individuals with Kabuki syndrome 
542 (reviewed in [120, 121]) but the gene associated with the condition was either KMT2D or 
543 not known, and there was a range of different cancers. It is not yet clear whether Kabuki 
544 syndrome, and specifically KDM6A mutation, is associated with an increased risk of specific 
545 cancers or cancer in general. The overall risk of cancer in women with Turner syndrome was 
546 no greater than the general population [122, 123] but they were at greater risk of 
547 gonadoblastoma (in cases where there was a 46XY lineage in addition to the 45X lineage), 
548 meningioma and childhood brain tumors [122] and possibly colon cancer [123]. A decreased 
549 risk of breast cancer in women with Turner syndrome [122] is consistent with the 
550 correlation between high KDM6A expression and poor prognosis in breast cancer (Section 
551 2.4)[103].
552 5.3 UTY as a minor histocompatibility antigen
553 Transplants between males and females are less successful than those between pairs of the 
554 same sex. This may be attributed to mismatching for minor histocompatibility antigens 
555 [124]. There are several of these that originate from the Y chromosome, including 
556 sequences within the UTY gene [125, 126]. Male recipients of HLA-identical female 
557 hematopoietic stem cell transplants were more likely to suffer graft versus host disease than 
558 male to male transplants, and his was exacerbated if there was a mismatch of the variant 
559 UTY peptide sequence with the paralogous sites of the donor’s KDM6A sequences. Graft 
560 versus host disease was not seen where the recipient UTY and donor KDM6A peptides were 
561 the same, suggesting that the donor immune system can see UTY as self if it matches its 
562 KDM6A [126]. Cytotoxic lymphocytes (CTL) from a female patient with aplastic anemia who 
563 rejected an HLA-identical stem cell transplant from a male donor were reactive to an 
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564 epitope at the N terminal end of UTY preceding the TPR domains [127]. Although there are 
565 three amino acid differences in the reference sequences for UTY and KDM6A for this 
566 epitope, only the first was recognised by the sensitised CTL. Reaction to this epitope was 
567 also found in a female who had had multiple blood transfusions. Another epitope, that 
568 sensitised female target cells to lysis by male CTL in vitro, was identified in the region 
569 between the highly conserved TPR and JmjC regions [125]. The equivalent region from the 
570 KDM6A gene differs by three amino acids and did not show sensitization [125]. These 
571 findings suggest possible treatment approaches by manipulating the minor 
572 histocompatibility antigens including the epitopes within UTY to target leukemia cells. 
573
574 6. Conclusions 
575 H3K27 demethylases perform an important catalytic function in mediating change in gene 
576 expression, whether it is during cell differentiation or activation, because they remove 
577 repressive marks from histones which opens the chromatin and facilitates transcription. The 
578 number of publications on KDM6A listed in PubMed 
579 (https://www.ncbi.nlm.nih.gov/pubmed) has increased annually from 1 in 2010 to 55 in 
580 2018 and 30 in the first quarter of 2019. In contrast, UTY has received very little attention 
581 with 4 papers in 2010 and 7 in 2018. In this review, KDM6A and UTY were analysed in detail 
582 to observe the level of similarity between these two genes, and assess the importance of 
583 UTY in cells. We have shown that UTY is co-regulated with KDM6A. It is proposed that UTY 
584 compensates for KDM6A in eutherian males and is responsible for the association between 
585 the loss of the Y chromosome and poor prognosis in a range of cancers. Given its role in 
586 oocyte maturation, development and carcinogenesis, KDM6A is a target for treatment of 
587 cancer and potentially infertility, but the contribution of UTY to maintenance of H3K27 
588 demethylation homeostasis should not be neglected.
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597 Table 1. Transcripts of human KDM6A and UTY. Data are taken from Ensembl 
598 (http://www.ensembl.org).
599 KDM6A
Transcript Ensembl ID Type Length 
(bp)
Protein 
length 
(aa)
Domains
201  ENST00000377967.8 Protein-
coding
5438 1401 TPR, JmjC
213  ENST00000611820.4 Protein-
coding
5924 1429 TPR, JmjC
202  ENST00000382899.8 Protein-
coding
5789 1384 TPR, JmjC
212  ENST00000543216.5 Protein-
coding
5655 1269 TPR, JmjC
211  ENST00000536777.5 Protein-
coding
5633 1332 TPR, JmjC
205  ENST00000433797.5 Protein-
coding
4324 1044 JmjC
203  ENST00000414389.5 Protein-
coding
4189 999 JmjC
23
214  ENST00000621147.4 Protein-
coding
2876 224 TPR
204  ENST00000431196.2 Protein-
coding
735 161 none
206  ENST00000451692.5 Protein-
coding
671 224 TPR
208  ENST00000479423.1 Processed 
transcript
768 NA NA
209  ENST00000484732.1 Processed 
transcript
640 NA NA
207  ENST00000475233.1 Processed 
transcript
612 NA NA
210  ENST00000485072.5 Processed 
transcript
382 NA NA
600
601
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602 UTY
Transcript Ensembl ID Type Length 
(bp)
Protein 
length 
(aa)
Domains
212 ENST00000545955.5 Protein-
coding
6817 1444 TPR, JmjC
214 ENST00000617789.4 Protein-
coding
6682 1399 TPR, JmjC
205 ENST00000382896.8 Protein-
coding
6661 1392 TPR, JmjC
211 ENST00000540140.5 Protein-
coding
6652 1389 TPR, JmjC
213 ENST00000612274.4 Protein-
coding
6586 1667 TPR, JmjC
210 ENST00000538878.5 Protein-
coding
6574 1363 TPR, JmjC
202 ENST00000331397.8 Protein-
coding
6529 1347 TPR, JmjC
209 ENST00000537580.5 Protein-
coding
6490 1335 TPR, JmjC
25
215 ENST00000618474.4 Protein-
coding
6277 1264 TPR, JmjC
203 ENST00000362096.8 Protein-
coding
4990 1240 TPR, JmjC
201 ENST00000329134.9 Protein-
coding
4325 1079 TPR
216 ENST00000624098.3 Protein-
coding
3636 1211 TPR, JmjC
204 ENST00000382893.2 Protein-
coding
1539 207 TPR
206 ENST00000474365.1 Processed 
transcript
1387 NA NA
207 ENST00000478900.5 Processed 
transcript
747 NA NA
208 ENST00000479713.1 Processed 
transcript
686 NA NA
603
604
605
606
607
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Table 2. Expression of UTY and neighbouring genes in human tissues and cells. Expression levels from the major transcription start sites taken 
from FANTOM5 (http:// fantom.gsc.riken.jp\zenbu).
Gene TTTY15 USP9Y DDX3Y UTY
Position (hg38) Y:12662367-12692224 Y:12701231-12804058 Y:12903985-12920478 Y:13248379-13480670
Strand Forward Forward Forward Reverse
Cell type with 
maximum 
expression 
(expression in TPM)
ARPE-19 cells 
undergoing EMT (152)
Monocyte derived 
macrophages 
responding to LPS (7)
CD4+ T-cells (779) CD4+ T-cells (131) 
Other high 
expressing cells 
(maximum 
expression in TPM)
Dendritic cells (115), 
CD4+ T-cells (105), 
CD8+ T-cells (93), 
CD19+ B-cells (69)
Mesenchymal stem 
cells undergoing 
adipogenesis (5), aortic 
smooth muscle cells (4), 
CD8+ T-cells (730), 
eosinophils (636), 
natural killer cells (603), 
basophils (577)
CD19+ B-cells (100), 
dendritic cells (100), 
natural killer cells (95), 
fetal thymus (92), fetal 
lung (87)
27
AML cell line (4), 
umbilical cord (3)
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Figure legends
Figure 1. KDM6A and UTY structure
A. Protein domains of the three JmjC lysine demethylases. TPR – tetratricopeptide repeats; 
JMJC – Jumonji C catalytic domain
B. Gene structure and transcription start sites in human. Images taken from FANTOM5 
Browser. Top panel – KDM6A; bottom panel - UTY. Upper tracks show the position, extent of 
gene determined by Ensembl, gene models from Gencode data, enhancers from FANTOM5 
data and identified CpG islands from UCSC data. Lower tracks show the number of tags at the 
TSS detected in the FANTOM5 study and the promoters identified after clustering of TSS [81] 
Green indicates transcription from the forward strand; purple indicates transcription from the 
reverse strand.
Figure 2. MegAlign CLUSTAL W comparison between Ensembl predicted amino acid 
sequences of KDM6A (based on ENST00000377967) and UTY (based on ENST00000545955). 
Highlighted yellow residues are conserved. The linker region between the two functional 
domains has been omitted.
A. Alignment of the TPR domains. The seven TPR domains are boxed in blue.
B. Alignment of the JmjC demethylase catalytic domain. The JmjC domain is boxed in red. 
Red asterisks denote catalytic sites in the JmjC domains. The green rectangle shown the 
amino acid change that has been previously reported to be associated with a reduction of 
the catalytic activity of UTY [9].
.                                                            .  Figure generated using MyDomains – Image Creator of 
Prosite  (https://prosite.expasy.org/). 
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Figure 3. Correlation of mRNA expression of UTY versus KDM6A.  Samples which had no 
expression of UTY were removed (probably female samples; verified with FANTOM5 
metadata where possible). 
A. All samples with UTY TPM >0. Pearson correlation coefficient = 0.720, N= 517, P < 0.0001.
B. All male tissues and non-cancerous cell types. Pearson correlation coefficient =0.727, N= 
439, P < 0.0001.
C. All cancer samples. Pearson correlation coefficient = 0.322, N= 78, P < 0.01.
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Supplementary Material
Supplementary Figure 1. Demethylation reaction catalysed by JmjC histone lysine demethylases 
(KDM). Lysines are linked by peptide bonds to adjacent amino acids (top of molecule). Red letters 
show the oxygen molecules. The unstable intermediate converts spontaneously to me2-lysine with 
the loss of formaldehyde (blue boxes). Dashed arrow indicates that the same reaction successively 
removes the remaining two methyl groups. The lysine molecule can then be acetylated (yellow 
boxes) by histone acetyl transferases (HAT). 
Supplementary Figure 2. Gene Tree created by Ensembl for KDM6A and UTY. The fully expanded 
tree is shown on the left and the structure of the gene is shown on the right. Sequences with large 
blocks of white are likely incomplete in the database. All samples in the UTY block (indicated by black 
bar) are male (where sex is known). DDX3Y is a neighbour of UTY on the human Y chromosome; 
proximity to the annotated DDX3Y in other species indicates that the gene identified is the UTY 
homolog. Additional information for samples in the UTY block was retrieved from Ensembl.  Note 
that KDM6A is on the X chromosome only in eutherian mammals; in all other species KDM6A is 
autosomal and they are not expected to have a UTY gene.
Supplementary Figure 3. Venn diagrams showing the overlap of transcription factors predicted to 
regulate KDM6A, KDM6B and UTY. A range of different approaches were used to identify 
transcription factors, as indicated above each diagram. Data taken from Harmonizome 
(http://amp.pharm.mssm.edu/Harmonizome/). 
Supplementary Figure 4. Venn diagram of the overlap of protein-protein actions predicted for 
KDM6A, KDM6B and UTY. Data taken from Harmonizome 
(http://amp.pharm.mssm.edu/Harmonizome/).
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Supplementary Figure 1. Demethylation reaction catalysed by JmjC histone lysine demethylases 
(KDM). Lysines are linked by peptide bonds to adjacent amino acids (top of molecule). Red letters 
show the oxygen molecules. The unstable intermediate converts spontaneously to me2-lysine with 
the loss of formaldehyde (blue boxes). Dashed arrow indicates that the same reaction successively 
removes the remaining two methyl groups. The lysine molecule can then be acetylated (yellow 
boxes) by histone acetyl transferases (HAT). Pathway based on information in [1-3]. 
Supplementary Figure 2. Full Gene Tree for KDM6A and UTY, generated by Ensembl 
(http://www.ensembl.org) and based on the longest protein coding translation. The tree shows the 
maximum likelihood phylogenetic tree representing the evolutionary history of the genes. Red 
squares represent duplication events, blue squares represent speciation events. See 
http://www.ensembl.org/Help/View?id=137 for further details of the methods used. The majority of 
the annotated genes are orthologs of KDM6A. UTY genes (by annotation or location on the Y 
chromosome) are indicated by a black bar at the right and are only found in eutherian mammals. 


Supplementary Figure 3. Venn diagrams showing the overlap of transcription factors predicted to 
regulate KDM6A, KDM6B and UTY. A range of different approaches were used to identify 
transcription factors, as indicated above each diagram. Data taken from Harmonizome 
(http://amp.pharm.mssm.edu/Harmonizome/).  
Supplementary Figure 4. Venn diagram of the overlap of protein-protein actions predicted for 
KDM6A, KDM6B and UTY. The genes in each section are listed in the boxes of the same color. Data 
taken from Harmonizome (http://amp.pharm.mssm.edu/Harmonizome/). 
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